Gilead Sciences ​is ‌nearing an acquisition ​of ​biotech firm ⁠Ouro ​Medicines ​for up to $2 billion, ​the ​Financial Times ‌reported ⁠on Monday, citing people ​familiar ​with ⁠the ​matter.